J. Baker

发表

Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.

A. Karsan, M. Fuller, Linda Chang, 2014, Cancer research.

Targeting the Tumour Vasculature: Exploitation of Low Oxygenation and Sensitivity to NOS Inhibition by Treatment with a Hypoxic Cytotoxin

A. Minchinton, A. Kyle, J. Baker, 2013, PloS one.

Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).

U. Häfeli, K. Saatchi, S. Reinsberg, 2016, Contrast media & molecular imaging.

Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts

S. Reinsberg, A. Minchinton, A. Kyle, 2014, Molecular Cancer Therapeutics.

In vivo Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Non–Muscle-Invasive Bladder Cancer

M. Gleave, R. Liggins, D. Brooks, 2011, Clinical Cancer Research.

Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium.

M. Gleave, L. Fazli, R. Liggins, 2012, Biomaterials.

Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin

M. Bally, A. Yung, P. Kozlowski, 2008, Clinical Cancer Research.

Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent.

Helen E. Burston, A. Minchinton, A. Kyle, 2003, Cancer research.

Opposing Roles for CD34 in B16 Melanoma Tumor Growth Alter Early Stage Vasculature and Late Stage Immune Cell Infiltration

M. Gold, C. Roskelley, M. Gold, 2011, PloS one.

Exploring vascular dysfunction caused by tirapazamine.

A. Minchinton, A. Kyle, J. Baker, 2008, Microvascular research.

Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically

S. C. Chafe, A. Bashashati, S. Shah, 2019, Cancer Immunology Research.

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

C. Scudamore, D. Owen, A. Buczkowski, 2010, British Journal of Cancer.

Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model

M. Bally, A. Minchinton, A. Kyle, 2021, International journal of molecular sciences.

Targeting quiescent tumor cells via oxygen and IGF-I supplementation.

Alastair H Kyle, A. Minchinton, Andrew I Minchinton, 2012, Cancer research.

Using Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Signal Transduction.

Jessica Kalra, Jennifer Baker, J. Baker, 2017, Methods in molecular biology.

Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts

Alastair H Kyle, A. Minchinton, Andrew I Minchinton, 2008, Clinical Cancer Research.

Targeting the tumour microenvironment : characterizing the anti-vascular effects of the hypoxic cytotoxin tirapazamine

J. Baker, 2010 .

Cancer Therapy : Preclinical In vivo Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Non – Muscle-Invasive Bladder Cancer

M. Gleave, R. Liggins, D. Brooks, 2011 .

Hyperbranched polyglycerols as trimodal imaging agents: design, biocompatibility, and tumor uptake.

U. Häfeli, D. Brooks, P. Soema, 2012, Bioconjugate chemistry.

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment

U. Häfeli, K. Saatchi, S. Reinsberg, 2018, Clinical & Experimental Metastasis.

Microregional Effects of Gemcitabine in HCT-116 Xenografts

A. Minchinton, A. Kyle, J. Baker, 2004, Cancer Research.

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment

U. Häfeli, K. Saatchi, S. Reinsberg, 2018, Clinical & Experimental Metastasis.

Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.

A. Minchinton, A. Kyle, J. Baker, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Multiplex Immunohistochemistry for Mapping the Tumor Microenvironment.

Jessica Kalra, Jennifer Baker, J. Baker, 2017, Methods in molecular biology.

Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assay.

K. Lam, A. Minchinton, A. Kyle, 2006, Microvascular research.

Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.

L. Bains, S. Reinsberg, A. Minchinton, 2009, International journal of radiation oncology, biology, physics.

DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost

A. Minchinton, A. Kyle, J. Baker, 2023, Scientific reports.

Targeting the tumour microenvironment : characterizing the anti-vascular effects of the hypoxic cytotoxin tirapazamine

J. Baker, 2010 .

DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.

A. Minchinton, A. Kyle, J. Baker, 2024, DNA repair.